Baxter International stock analysis
Baxter International (BTL) Stock Price & Analysis
BTL Stock Chart & Stats
- Day’s Range
- EUR 23.24 - EUR 23.58
- 52-Week Range
- EUR 13.66 - EUR 24.75
- Previous Close
- EUR 22.87
- Volume
- N/A
- Average Volume (3M)
- 47
- Market Cap
- EUR 11.98B
- Enterprise Value
- EUR 18.49B
- Total Cash (Recent Filing)
- EUR 1.98B
- Total Debt (Recent Filing)
- EUR 8.81B
- Price to Earnings (P/E)
- ―
- Beta
- 1.17
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 0.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.14%
Bulls Say, Bears Say
Bulls Say
Recurring Clinical-Use Demand
Routine use of IV solutions, renal-therapy consumables and single-use products creates repeat purchasing tied to patient treatments rather than discretionary demand. This recurring model can support revenue resilience and customer retention across hospitals, dialysis providers and clinics.
Broad-Based Revenue Growth
Growth is broad enough to indicate improving execution across multiple businesses rather than reliance on one product. Raised organic guidance and contributions from Medical Products and Therapies and Healthcare Systems and Technologies support a constructive revenue trajectory over coming quarters.
Deleveraging And Operational Improvement
Debt retirement directly improves financial flexibility, while the Baxter GPS program provides a structured process for reducing waste and improving execution. Together, these actions can strengthen future cash conversion and support investment in the core business over time.
Bears Say
Persistent Net Losses
Persistent net losses show that revenue recovery has not yet translated into durable shareholder earnings. With EBITDA still modest at about a 7% margin, Baxter has less internal capacity to fund growth, absorb setbacks or reduce debt without further operating improvement.
Weak Cash Conversion And Leverage
Thin free cash flow reduces the company’s ability to deleverage, invest and maintain financial resilience at the same time. Although debt has declined, cash generation remains weak relative to obligations, leaving execution and profitability improvements important for balance-sheet stability.
Round Lake Regulatory Exposure
The FDA warning letter indicates an ongoing quality and compliance remediation burden at a strategically important facility. Continued regulatory work can consume management attention, constrain production flexibility and create lasting execution risk until the observations are fully addressed.
Baxter International News
Baxter International Faces Investor Class Action as Defendants Move to Dismiss Securities Claims Over Novum IQ Pump Disclosures
Baxter International Inc. ($BAX) and five current and former executives have asked a federal court to dismiss a securities class action accusing the company of misleading investors about its Novum
BTL FAQ
What was Baxter International’s price range in the past 12 months?
What is Baxter International’s market cap?
When is Baxter International’s upcoming earnings report date?
How were Baxter International’s earnings last quarter?
Is Baxter International overvalued?
Does Baxter International pay dividends?
What is Baxter International’s EPS estimate?
How many shares outstanding does Baxter International have?
What happened to Baxter International’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Baxter International?
What is the TipRanks Smart Score and how is it calculated?
Baxter International Stock Smart Score
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider
- Employees
- 37,500
- Website
- www.baxter.com
- Address
- One Baxter Parkway, Deerfield, IL, 60015, US
Baxter International (BTL) Earnings & Revenues
BTL Company Deck
BTL Earnings Call
Earnings Call SentimentPositive
The call was broadly constructive and reflected improving execution, strong free cash flow, deleveraging progress, segment growth and raised full-year guidance. Management also highlighted ongoing challenges, including lower adjusted earnings, injectables and cephalosporin-related issues, lower margins, inflation, tariffs and several 2027 headwinds. Highlights significantly outweighed the lowlights, while management acknowledged that further work is required to improve consistency and execution.
View all DE:BTL earnings summariesBTL Net sales Breakdown
- 47.13% Medical Products and Therapies
- 27.31% Healthcare Systems and Technologies
- 22.17% Pharmaceuticals
- 3.39% Other
BTL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |












